Where does AIM ImmunoTech Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), AIM ImmunoTech Inc. ranks #44,516 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does AIM ImmunoTech Inc. hold?

AIM ImmunoTech Inc. holds 5 US utility patents granted between 2023 and 2025, spanning 9 technology areas.

What is AIM ImmunoTech Inc.'s Innovation Score?

AIM ImmunoTech Inc. has an Innovation Score of 46.2 out of 100 (top 21% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does AIM ImmunoTech Inc. focus on?

AIM ImmunoTech Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 5 patents, ranking #3,434 of 6,058 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is AIM ImmunoTech Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for AIM ImmunoTech Inc..

What does claim depth mean for AIM ImmunoTech Inc.'s patents?

AIM ImmunoTech Inc.'s patents average 15.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the AIM ImmunoTech Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

AIM ImmunoTech Inc.

USPTO PatentsView assignee record - 5 granted patents across 9 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, AIM ranks #44,516 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 9 technology areas.

#44,516
of 49,997 US assignees by volume: Top 21%
by Innovation Score (46.2/100): 15.6
avg claims per patent

USPTO PatentsView assignee plate

Corpus R44516 · US Corporation #44,516 · 5 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 5 grants
LOWER-Q #44,516/49,997
PHOTO-FINISH Ai-musics Technology
CPC-NARROW A61P · 9 areas
INNOV-PAR 46.2/100
CLAIMS-RICH 15.6 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2023–2025 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Ai-musics Technology Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How AIM’s 46.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (13%) Velocity 20.0 pts (43%) Breadth 10.6 pts (23%) Claim depth 9.4 pts (20%)

Qualcomm Incorporated · highest

85
AIM ImmunoTech · this assignee

46
3D Lighting… · lowest

7

What this shows AIM's Innovation Score is 46.2/100 (top 21% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for AIM?

Each dot is one of AIM’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). AIM’s own 15.6 claims/patent is ABOVE the 13.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

AIM vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where AIM's grants concentrate

AIM ImmunoTech Inc. is a focused PatentsView assignee: 9 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2023 (3 grants) versus a trough of 1 in 2024. By volume, AIM sits between Ai-musics Technology Inc. and Aion Co., Ltd..

AIM's three-year grant acceleration

AIM ImmunoTech Inc. shows 4 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Ai-musics Technol…

5
Aikawa Fiber OY

5
AIL International

5
AIL Research

5
AIM Sports

5
Aim3d

5
Aimed BIO

5
Aion

5
AIM Immunotech ◀

5

What this shows AIM holds 5 patents at rank #44,452, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near AIM

By rank, the assignees closest to #44,452 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in AIM's primary technology class.

AIM's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 21% higher than 79% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table

AIM ImmunoTech Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2023	3	60.0%
2024	1	20.0%
2025partial year	1	20.0%

Which technologies does AIM ImmunoTech Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

C07K - Peptides 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

AIM ImmunoTech Inc.'s patent record in context - here's where to go next.

AIM ImmunoTech Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #44,516 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare AIM ImmunoTech Inc. against Ai-musics Technology Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 46.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.